United States · Platforms & data · The Motley Fool

Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine

Published by The Motley Fool · United States 1 h ago

Jazz Pharmaceuticals' strategy is starting to pay dividends.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Greenbrier Companies, Inc. (The) (NYSE:GBX) Stock Has Average Price Target of $42.67

Is that used EV worth the price? This checklist could save you thousands of dollars.

Robinhood CEO’s AI startup Harmonic expands into software, chip design verification

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Galaxy Digital Stock Surges After Quarterly Earnings Crush Estimates

Novartis Raises Guidance After Trial Setbacks Hit Profit